Summary
Global Markets Direct’s, ‘CureVac GmbH - Product Pipeline Review - 2016’, provides an overview of the CureVac GmbH’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH
- The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses CureVac GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features CureVac GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate CureVac GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for CureVac GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding CureVac GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
CureVac GmbH Snapshot 6
CureVac GmbH Overview 6
Key Information 6
Key Facts 6
CureVac GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
CureVac GmbH - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
CureVac GmbH - Pipeline Products Glance 16
CureVac GmbH - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
CureVac GmbH - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
CureVac GmbH - Drug Profiles 20
CV-9104 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CV-9103 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CV-9201 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CV-8102 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
nadorameran 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Oligonucleotide for Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Oligonucleotide for Infectious Disease 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Oligonucleotide for Influenza Virus Infection 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Oligonucleotide for respiratory syncytial virus vaccine 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
infectious disease vaccine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Oligonucleotide for HIV 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Oligonucleotide for Respiratory Syncytial Virus-1 Infection 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Oligonucleotide for Rotavirus Infection 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Oligonucleotide for Undisclosed Indication 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Oligonucleotides for Undisclosed Indication 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Vaccine 1 for oncology 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaccine for Oncology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CureVac GmbH - Pipeline Analysis 40
CureVac GmbH - Pipeline Products by Target 40
CureVac GmbH - Pipeline Products by Route of Administration 41
CureVac GmbH - Pipeline Products by Molecule Type 42
CureVac GmbH - Recent Pipeline Updates 43
CureVac GmbH - Dormant Projects 46
CureVac GmbH - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
CureVac GmbH, Key Information 6
CureVac GmbH, Key Facts 6
CureVac GmbH - Pipeline by Indication, 2016 9
CureVac GmbH - Pipeline by Stage of Development, 2016 10
CureVac GmbH - Monotherapy Products in Pipeline, 2016 11
CureVac GmbH - Partnered Products in Pipeline, 2016 12
CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2016 13
CureVac GmbH - Out-Licensed Products in Pipeline, 2016 14
CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
CureVac GmbH - Phase II, 2016 16
CureVac GmbH - Phase I, 2016 17
CureVac GmbH - Preclinical, 2016 18
CureVac GmbH - Discovery, 2016 19
CureVac GmbH - Pipeline by Target, 2016 40
CureVac GmbH - Pipeline by Route of Administration, 2016 41
CureVac GmbH - Pipeline by Molecule Type, 2016 42
CureVac GmbH - Recent Pipeline Updates, 2016 43
CureVac GmbH - Dormant Developmental Projects,2016 46
CureVac GmbH, Other Locations 47
List of Figures
CureVac GmbH - Pipeline by Top 10 Indication, 2016 8
CureVac GmbH - Pipeline by Stage of Development, 2016 10
CureVac GmbH - Monotherapy Products in Pipeline, 2016 11
CureVac GmbH - Out-Licensed Products in Pipeline, 2016 14
CureVac GmbH - Pipeline by Top 10 Target, 2016 40
CureVac GmbH - Pipeline by Route of Administration, 2016 41
CureVac GmbH - Pipeline by Molecule Type, 2016 42
